Intravitreal aflibercept for choroidal neovascularization associated with chorioretinitis: a pilot study

Figures & data

Table 1 One-year follow-up of intravitreal aflibercept for choroidal neovascularization associated with chorioretinitis

Patient	Sex	Age (years)	Eye	Diagnosis	Pretreatment BCVA	Posttreatment BCVA	Pretreatment mean retinal thickness in fovea (µm)	Posttreatment mean retinal thickness in fovea (µm)	Number of intravitreal injections
1	F	46	R	TX	0.6	0.65	290	254	1
			L	TX	0.7	0.8	265	228	2
2	F	28	L	TX	0.3	1.0	274	231	2
3	F	23	R	TX	0.1	0.2	528	362	2
4	F	29	R	TX	0.5	0.8	327	242	1
5	M	16	R	TX	0.3	0.9	382	297	2
6	F	56	L	TX	0.8	0.9	345	274	1
7	M	54	L	TX	0.5	0.8	242	215	1
8	F	28	R	TX	0.3	1.0	239	192	2
9	F	36	R	TX	0.15	0.25	382	299	1
10	F	42	L	TX	0.06	0.15	320	242	2
11	F	39	R	TX	0.45	0.7	265	212	2
12	M	44	R	TX	0.1	0.25	328	279	2
13	F	26	L	TX	0.35	0.75	262	221	2
14	F	56	R	TX	0.16	0.4	304	258	2

Abbreviations: BCVA, best-corrected visual acuity; F, female; L, left; M, male; R, right; TX, toxoplasmosis.

Figure 1 (A) Baseline fundus photographs (OS) show a macular scar with fibrosis, subretinal fluid, and hemorrhage. (B) Baseline optical coherence tomographic (OCT) scan shows increased retinal thickening and a highly reflective subretinal complex. (C and D) Baseline early- and late-phase fluorescein angiographic images show leakage from choroidal neovascularization. (E) Posttreatment fundus photographs taken at 4 months show a macular scar and no evidence of subretinal fluid or hemorrhage. (F) Posttreatment OCT scan taken at 4 months shows decreased retinal thickness and a persistent highly reflective subretinal complex. (G and H) Posttreatment early- and late-phase fluorescein angiographic images taken at 4 months show no evidence of leakage.